COSM: COSM inks 3-year CMO deal to make 3.9M progesterone pessaries for Verisfield

AI Summary

Cosmos Health (NASDAQ: COSM) said subsidiary Cana Laboratories signed a three-year contract manufacturing agreement to produce 1.3M VASCLOR GEST (progesterone) 400 mg vaginal pessaries per year (3.9M units total) for luteal phase support and assisted reproduction. The deal expands Cana's EU GMP/EMA-certified contract-manufacturing footprint into women's health and is described as a higher-margin, recurring revenue stream, though the company disclosed no pricing so the financial impact is unclear.

Positives

Three-year agreement for 3.9M units total (1.3M units/year) of VASCLOR GEST 400 mg pessaries
Uses Cana's European GMP/EMA-certified manufacturing capacity, expanding into women's health/reproductive medicine
Company describes the deal as expanding its high-margin contract manufacturing book and diversifying customers

Negatives

No financial terms disclosed, so revenue and margin contributions are unknown
Total volume (3.9M units over three years) may represent a modest revenue boost
Commercial performance depends on Verisfield's ability to market and distribute the product